1: Barbieri MA, Nielsen SMN, Rossi A, Olmastroni E, Casula M, Spina E, Sessa M. A newly developed method for assessing co-exposure to free dose combinations: a proof-of-concept study using antihypertensive medications in Danish registers. Aging Clin Exp Res. 2024 Nov 26;36(1):226. doi: 10.1007/s40520-024-02879-4.

2: Olmastroni E, Scotti S, Galimberti F, Xie S, Casula M. Ezetimibe: Integrating Established Use with New Evidence – A Comprehensive Review. Curr Atheroscler Rep. 2024 Nov 25;27(1):10. doi: 10.1007/s11883-024-01248-w.

3: Rossi A, Perrella L, Scotti S, Olmastroni E, Galimberti F, Ardoino I, Orlando V, Menditto E, Franchi C, Casula M. Approaches to Deprescribing Proton Pump Inhibitors in Clinical Practice: A Systematic Review. J Clin Med. 2024 Oct 21;13(20):6283. doi: 10.3390/jcm13206283.

4: European Atherosclerosis Society Familial Hypercholesterolaemia Studies Collaboration (EAS FHSC). Association of BMI, lipid-lowering medication, and age with prevalence of type 2 diabetes in adults with heterozygous familial hypercholesterolaemia: a worldwide cross-sectional study. Lancet Diabetes Endocrinol. 2024 Nov;12(11):811-823. doi: 10.1016/S2213-8587(24)00221-3.

5: Xie S, Galimberti F, Olmastroni E, Catapano AL, Casula M. Effect on C-reactive protein levels of the addition of ezetimibe, bempedoic acid, or colchicine to statin treatment: A network meta-analysis. J Intern Med. 2024 Sep;296(3):302-305. doi: 10.1111/joim.13824.

6: Baragetti A, Grigore L, Olmastroni E, Mattavelli E, Catapano AL. Plasma proteins associate with carotid plaques and predict incident atherosclerotic cardiovascular events. Vascul Pharmacol. 2024 Sep;156:107394. doi: 10.1016/j.vph.2024.107394.

7: Cattaneo M, Baragetti A, Malovini A, Ciaglia E, Lopardo V, Olmastroni E, Casula M, Ciacci C, Catapano AL, Puca AA. Longevity-associated BPIFB4 gene counteracts the inflammatory signaling. Immun Ageing. 2024 Mar 12;21(1):19. doi: 10.1186/s12979-024-00424-5.

8: Xie S, Galimberti F, Olmastroni E, Luscher TF, Carugo S, Catapano AL, Casula M; META-LIPID Group. Effect of lipid-lowering therapies on C-reactive protein levels: a comprehensive meta-analysis of randomized controlled trials. Cardiovasc Res. 2024 Mar 30;120(4):333-344. doi: 10.1093/cvr/cvae034.

9: Alieva A, Di Costanzo A, Gazzotti M, Reutova O, Usova E, Bakaleiko V, Arca M, D’Erasmo L, Pellegatta F, Galimberti F, Olmastroni E, Catapano AL, Casula M. Genetic heterogeneity of familial hypercholesterolaemia in two populations from two different countries. Eur J Intern Med. 2024 May;123:65-71. doi: 10.1016/j.ejim.2024.01.010.

10: European Atherosclerosis Society Familial Hypercholesterolaemia Studies Collaboration. Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study. Lancet. 2024 Jan 6;403(10421):55-66. doi: 10.1016/S0140-6736(24)01409-0.

11: Casula M, Gazzotti M, Capra ME, Olmastroni E, Galimberti F, Catapano AL, Pederiva C; LIPIGEN Group and the LIPIGEN Paediatric Group. Refinement of the diagnostic approach for the identification of children and adolescents affected by familial hypercholesterolemia: Evidence from the LIPIGEN study. Atherosclerosis. 2023 Nov;385:117231. doi: 10.1016/j.atherosclerosis.2023.117231.

12: Galimberti F, Casula M, Olmastroni E. Apolipoprotein B compared with low-density lipoprotein cholesterol in the atherosclerotic cardiovascular diseases risk assessment. Pharmacol Res. 2023 Sep;195:106873. doi: 10.1016/j.phrs.2023.106873.

13: Olmastroni E, Gazzotti M, Averna M, Arca M, Tarugi P, Calandra S, Bertolini S, Catapano AL, Casula M; LIPIGEN Study Group *. Lipoprotein(a) Genotype Influences the Clinical Diagnosis of Familial Hypercholesterolemia. J Am Heart Assoc. 2023 May 16;12(10):e029223. doi: 10.1161/JAHA.122.029223.

14: Gazzotti M, Casula M, Bertolini S, Capra ME, Olmastroni E, Catapano AL, Pederiva C; LIPIGEN Paediatric Group. The role of registers in increasing knowledge and improving management of children and adolescents affected by familial hypercholesterolemia: The LIPIGEN pediatric group. Front Genet. 2023 Apr 18;14:1113454. doi: 10.3389/fgene.2023.1113454.

15: Mattavelli E, Olmastroni E, Casula M, Grigore L, Pellegatta F, Baragetti A, Magni P, Catapano AL. Adherence to Mediterranean Diet: A Population-Based Longitudinal Cohort Study. Nutrients. 2023 Apr 12;15(8):1844. doi: 10.3390/nu15081844.

16: Olmastroni E, Galimberti F, Tragni E, Catapano AL, Casula M. Impact of COVID-19 Pandemic on Adherence to Chronic Therapies: A Systematic Review. Int J Environ Res Public Health. 2023 Feb 21;20(5):3825. doi: 10.3390/ijerph20053825.

17: Catapano AL, Tokgözoğlu L, Banach M, Gazzotti M, Olmastroni E, Casula M, Ray KK; Lipid Clinics Network Group. Evaluation of lipoprotein(a) in the prevention and management of atherosclerotic cardiovascular disease: A survey among the Lipid Clinics Network. Atherosclerosis. 2023 Apr;370:5-11. doi: 10.1016/j.atherosclerosis.2023.02.007.

18: Olmastroni E, Galimberti F, Catapano AL, Tragni E, Casula M. Beta-blockers in post-acute myocardial infarction patients: Drug prescription patterns from 2018 to Italy’s first wave of the COVID-19 pandemic. Front Pharmacol. 2022 Dec 7;13:1040710. doi: 10.3389/fphar.2022.1040710.

19: Galimberti F, Casula M, Olmastroni E, Catapano AL, Tragni E, On Behalf Of Edu Re Drug Group. Antibiotic Prescription in the Community-Dwelling Elderly Population in Lombardy, Italy: A Sub-Analysis of the EDU.RE.DRUG Study. Antibiotics (Basel). 2022 Oct 7;11(10):1369. doi: 10.3390/antibiotics11101369.

20: Casula M, Galimberti F, Iommi M, Olmastroni E, Rosa S, Altini M, Catapano AL, Tragni E, Poluzzi E. Impact of the COVID-19 Pandemic on the Therapeutic Continuity among Outpatients with Chronic Cardiovascular Therapies. Int J Environ Res Public Health. 2022 Sep 24;19(19):12101. doi: 10.3390/ijerph191912101.

21: Curia MC, Pignatelli P, D’Antonio DL, D’Ardes D, Olmastroni E, Scorpiglione L, Cipollone F, Catapano AL, Piattelli A, Bucci M, Magni P. Oral Porphyromonas gingivalis and Fusobacterium nucleatum Abundance in Subjects in Primary and Secondary Cardiovascular Prevention, with or without Heterozygous Familial Hypercholesterolemia. Biomedicines. 2022 Aug 31;10(9):2144. doi: 10.3390/biomedicines10092144

22: Gazzotti M, Casula M, Bertolini S, Capra ME, Olmastroni E, Catapano AL, Pederiva C; LIPIGEN Paediatric Group. The Role of Registers in Increasing Knowledge and Improving Management of Children and Adolescents Affected by Familial Hypercholesterolemia: the LIPIGEN Pediatric Group. Front Genet. 2022 Jun 20;13:912510. doi: 10.3389/fgene.2022.912510. Erratum in: Front Genet. 2023 Apr 18;14:1113454. doi: 10.3389/fgene.2023.1113454.

23: Mucherino S, Casula M, Galimberti F, Guarino I, Olmastroni E, Tragni E, Orlando V, Menditto E, On Behalf Of The Edu Re Drug Group. The Effectiveness of Interventions to Evaluate and Reduce Healthcare Costs of Potentially Inappropriate Prescriptions among the Older Adults: A Systematic Review. Int J Environ Res Public Health. 2022 May 31;19(11):6724. doi: 10.3390/ijerph19116724.

24: Mattavelli E, Olmastroni E, Bonofiglio D, Catapano AL, Baragetti A, Magni P. Adherence to the Mediterranean Diet: Impact of Geographical Location of the Observations. Nutrients. 2022 May 13;14(10):2040. doi: 10.3390/nu14102040.

25: Pederiva C, Capra ME, Biasucci G, Banderali G, Fabrizi E, Gazzotti M, Casula M, Catapano AL; LIPIGEN Paediatric Group; MEMBERS OF THE LIPIGEN STEERING COMMITTEE; Arca M, Averna M, Bertolini S, Calandra S, Catapano AL, Tarugi P; PRINCIPAL INVESTIGATORS; Coordinator center; Pellegatta F; Participant Centers; Participant COLLABORATORS; STUDY COORDINATING GROUP. Lipoprotein(a) and family history for cardiovascular disease in paediatric patients: A new frontier in cardiovascular risk stratification. Data from the LIPIGEN paediatric group. Atherosclerosis. 2022 May;349:233-239. doi: 10.1016/j.atherosclerosis.2022.04.021.

26: Galimberti F, Olmastroni E, Casula M, Merlo I, Franchi M, Catapano AL, Orlando V, Menditto E, Tragni E, Edu Re Drug Group OBO. Evaluation of Factors Associated With Appropriate Drug Prescription and Effectiveness of Informative and Educational Interventions-The EDU.RE.DRUG Project. Front Pharmacol. 2022 Apr 25;13:832169. doi: 10.3389/fphar.2022.832169.

27: Galimberti F, Casula M, Scotti L, Olmastroni E, Ferrante D, Ucciero A, Tragni E, Catapano AL, Barone-Adesi F. Potentially Inappropriate Prescribing among Elderly Outpatients: Evaluation of Temporal Trends 2012-2018 in Piedmont, Italy. Int J Environ Res Public Health. 2022 Mar 18;19(6):3612. doi: 10.3390/ijerph19063612.

28: Olmastroni E, Gazzotti M, Arca M, Averna M, Pirillo A, Catapano AL, Casula M; LIPIGEN Study Group†. Twelve Variants Polygenic Score for Low-Density Lipoprotein Cholesterol Distribution in a Large Cohort of Patients With Clinically Diagnosed Familial Hypercholesterolemia With or Without Causative Mutations. J Am Heart Assoc. 2022 Apr 5;11(7):e023668. doi: 10.1161/JAHA.121.023668.

29: Baragetti A, Casula M, Scarinzi P, Ristè F, Scicali R, Biolo M, Lugari S, Dall’Agata M, Gazzotti M, Olmastroni E, Alieva AS, Nascimbeni F; ACTUS-FH LIPIGEN Substudy. Achilles tendon ultrasonography in familial hypercholesterolemia: A sub-study of the LIpid transPort disorders Italian GEnetic Network (LIPIGEN). J Intern Med. 2022 May;291(5):702-704. doi: 10.1111/joim.13421.

30: Olmastroni E, Molari G, De Beni N, Colpani O, Galimberti F, Gazzotti M, Zambon A, Catapano AL, Casula M. Statin use and risk of dementia or Alzheimer’s disease: a systematic review and meta-analysis of observational studies. Eur J Prev Cardiol. 2022 May 5;29(5):804-814. doi: 10.1093/eurjpc/zwab208.

31: EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Lancet. 2021 Nov 6;398(10312):1713-1725. doi: 10.1016/S0140-6736(21)01122-3.

32: Pirillo A, Casula M, Olmastroni E, Norata GD, Catapano AL. Global epidemiology of dyslipidaemias. Nat Rev Cardiol. 2021 Oct;18(10):689-700. doi: 10.1038/s41569-021-00541-4.

33: Alieva AS, Olmastroni E, Reutova OV, Rotar OP, Konradi AO, Shlyakhto EV, Baragetti A, Grigore L, Pellegatta F, Casula M, Tragni E, Catapano AL. Prevalence and relationship between metabolic syndrome and risk of cardiovascular disease: Evidence from two population-based studies. Atheroscler Suppl. 2020 Dec;42:e41-e48. doi: 10.1016/j.atherosclerosissup.2021.01.008.

34: Gazzotti M, Casula M, Olmastroni E, Averna M, Arca M, Catapano AL. How registers could enhance knowledge and characterization of genetic dyslipidaemias: The experience of the LIPIGEN in Italy and of other networks for familial hypercholesterolemia. Atheroscler Suppl. 2020 Dec;42:e35-e40. doi: 10.1016/j.atherosclerosissup.2021.01.007.

35: Cicolari S, Pavanello C, Olmastroni E, Puppo MD, Bertolotti M, Mombelli G, Catapano AL, Calabresi L, Magni P. Interactions of Oxysterols with Atherosclerosis Biomarkers in Subjects with Moderate Hypercholesterolemia and Effects of a Nutraceutical Combination (Bifidobacterium longum BB536, Red Yeast Rice Extract) (Randomized, Double-Blind, Placebo-Controlled Study). Nutrients. 2021 Jan 28;13(2):427. doi: 10.3390/nu13020427.

36: Baragetti A, Severgnini M, Olmastroni E, Dioguardi CC, Mattavelli E, Angius A, Rotta L, Cibella J, Caredda G, Consolandi C, Grigore L, Pellegatta F, Giavarini F, Caruso D, Norata GD, Catapano AL, Peano C. Gut Microbiota Functional Dysbiosis Relates to Individual Diet in Subclinical Carotid Atherosclerosis. Nutrients. 2021 Jan 21;13(2):304. doi: 10.3390/nu13020304.

37: Casula M, Olmastroni E, Gazzotti M, Galimberti F, Zambon A, Catapano AL. Omega-3 polyunsaturated fatty acids supplementation and cardiovascular outcomes: do formulation, dosage, and baseline cardiovascular risk matter? An updated meta-analysis of randomized controlled trials. Pharmacol Res. 2020 Oct;160:105060. doi: 10.1016/j.phrs.2020.105060.

38: Russo V, Orlando V, Monetti VM, Galimberti F, Casula M, Olmastroni E, Tragni E, Menditto E; EDU.RE.DRUG Group. Geographical Variation in Medication Prescriptions: A Multiregional Drug-Utilization Study. Front Pharmacol. 2020 May 5;11:418. doi: 10.3389/fphar.2020.00418.

39: Casula M, Olmastroni E, Galimberti F, Tragni E, Corrao G, Scotti L, Catapano AL. Association between the cumulative exposure to bisphosphonates and hospitalization for atherosclerotic cardiovascular events: A population-based study. Atherosclerosis. 2020 May;301:1-7. doi: 10.1016/j.atherosclerosis.2020.03.021.

40: Olmastroni E, Boccalari MT, Tragni E, Rea F, Merlino L, Corrao G, Catapano AL, Casula M. Sex-differences in factors and outcomes associated with adherence to statin therapy in primary care: Need for customisation strategies. Pharmacol Res. 2020 May;155:104514. doi: 10.1016/j.phrs.2019.104514.

41: Olmastroni E, Baragetti A, Casula M, Grigore L, Pellegatta F, Pirillo A, Tragni E, Catapano AL. Multilevel Models to Estimate Carotid Intima-Media Thickness Curves for Individual Cardiovascular Risk Evaluation. Stroke. 2019 Jul;50(7):1758-1765. doi: 10.1161/STROKEAHA.118.024692.

42: Casula M, Olmastroni E, Boccalari MT, Tragni E, Pirillo A, Catapano AL. Cardiovascular events with PCSK9 inhibitors: an updated meta-analysis of randomised controlled trials. Pharmacol Res. 2019 May;143:143-150. doi: 10.1016/j.phrs.2019.03.021.

43: Casula M, Olmastroni E, Pirillo A, Catapano AL; MEMBERS OF THE LIPIGEN STEERING COMMETTEE; PRINCIPAL INVESTIGATORS: Coordinator center; Participant Centers; Participant Laboratories; COLLABORATORS; STUDY CENTRAL LABORATORY AND ANALYSIS GROUP. Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: The LIPIGEN study. Atherosclerosis. 2018 Oct;277:413-418. doi: 10.1016/j.atherosclerosis.2018.08.013.

44: Olmastroni E, Shlyakhto EV, Konradi AO, Rotar OP, Alieva AS, Boyarinova MA, Baragetti A, Grigore L, Pellegatta F, Tragni E, Catapano AL, Casula M. Epidemiology of cardiovascular risk factors in two population-based studies. Atheroscler Suppl. 2018 Sep;35:e14-e20. doi: 10.1016/j.atherosclerosissup.2018.08.003.

45: Baragetti A, Grejtakova D, Casula M, Olmastroni E, Jotti GS, Norata GD, Catapano AL, Bellosta S. Proprotein Convertase Subtilisin-Kexin type-9 (PCSK9) and triglyceride-rich lipoprotein metabolism: Facts and gaps. Pharmacol Res. 2018 Apr;130:1-11. doi: 10.1016/j.phrs.2018.01.025.